Core Viewpoint - The company has approved several key resolutions during its board meeting, including the signing of an exclusive supply agreement for Efparepoetin alfa and the transfer of equity stakes in its subsidiary [1][2]. Group 1: Exclusive Supply Agreement - The company’s subsidiary, Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd., plans to sign an exclusive supply agreement with GOODFELLOW PHARMA CORPORATION for the drug Efparepoetin alfa in the Philippines [1]. - GOODFELLOW will act as the exclusive agent in the target region for the registration, clinical trials, promotion, distribution, and sales of Efparepoetin alfa [1]. Group 2: Equity Transfer - The company intends to transfer 2.00% of the equity in its subsidiary Jinan Buchang Caikan Trading Co., Ltd. to He Tao, and another 2.00% to Fang Ke Rui, while 1.00% will be transferred to 1929 Health Technology (Guangzhou) Co., Ltd. [2]. - The transfer price for these equity stakes is set at 0 yuan, resulting in the company retaining a 90% ownership stake in Buchang Caikan after the transfers [2]. Group 3: Name and Address Change - The subsidiary Jinan Buchang Caikan Trading Co., Ltd. plans to change its registered address and name for operational management needs [3]. - This change has also been approved by the board and will be submitted for further review [3].

Core Viewpoint - The company plans to transfer a total of 5% equity in its subsidiary, Jinan Buchang Caigan Trading Co., Ltd., to various individuals and entities for a nominal price of 0 RMB, reducing its ownership from 93% to 90% [1][2][3] Transaction Overview - The company will transfer 2% equity to He Tao, 2% to Xie Jihui, and 1% to 1929 Health Technology (Guangzhou) Co., Ltd. [1][2] - The transaction does not constitute a related party transaction or a major asset restructuring as defined by regulations, and does not require shareholder approval [1][3] - There are no significant legal obstacles to the transaction [1][3] Parties Involved - The transferors include Fang Ke Rui, who is the General Manager of Shandong Buchang Qihang Pharmaceutical Sales Co., Ltd., and Zhou Yan Feng, who is the Regional Manager [3][4] - The transferee, 1929 Health Technology (Guangzhou) Co., Ltd., is a limited liability company with a registered capital of 1 million RMB and has been operating since November 2, 2022 [4][5] Financial Data of the Subsidiary - As of June 30, 2025, Buchang Caigan has not commenced actual business operations and thus has no financial data [5][6] - The company has a registered capital of 1 million RMB and is involved in various trading activities including medical supplies and health products [5][6] Impact on the Company - The equity transfer aligns with the company's strategic development and long-term interests, and is not expected to adversely affect its financial status or future operating results [7] - The company will continue to monitor market risks, management risks, and operational risks associated with the transaction [7]

Core Viewpoint - The company aims to enhance its internationalization strategy and brand influence by signing an exclusive supply agreement with GOODFELLOW PHARMA CORPORATION for the product Efparepoetin alfa in the Philippines [1][6]. Summary by Sections Agreement Overview - The board of directors approved the exclusive supply agreement with GOODFELLOW for the product Efparepoetin alfa, which is currently under registration [2]. - The agreement does not involve related party transactions or constitute a major asset restructuring [2][3]. Product Information - Efparepoetin alfa is a new biological drug intended for treating anemia in adult dialysis patients due to chronic kidney disease (CKD) and has submitted a listing application [2]. - As of June 30, 2025, the cumulative R&D investment in Efparepoetin alfa is approximately 498.92 million yuan [2]. Partner Information - GOODFELLOW PHARMA CORPORATION, established in 2004, is based in Metro Manila, Philippines, and specializes in the import and export of medical products [3][4]. - There is no related party relationship between GOODFELLOW and the company [4]. Agreement Details - GOODFELLOW is authorized as the exclusive agent in the Philippines for the registration, clinical trials, promotion, distribution, and sales of Efparepoetin alfa [4][5]. - The agreement includes provisions for product registration, with the company responsible for preparing necessary documentation and providing product samples for clinical research [5]. - The agreement is effective for five years from the date of obtaining the import drug license, with a potential five-year extension [5][6]. Impact on the Company - This transaction represents a significant step in the company's internationalization strategy, expected to generate economic benefits and enhance brand value [6][7]. - The collaboration aims to expedite the commercialization of R&D results and expand the overseas market for Efparepoetin alfa, thereby improving the company's performance [7].

Core Viewpoint - The company is advancing its internationalization strategy by signing an exclusive supply agreement with GOODFELLOW in the Philippines for the product Efparepoetin alfa, aimed at enhancing economic benefits and brand influence [1][2] Group 1: Strategic Initiatives - The agreement allows the subsidiary Luzhou Bichang Biopharmaceutical Co., Ltd. to appoint GOODFELLOW as the exclusive agent for the registration, clinical trials, promotion, distribution, and sales of Efparepoetin alfa in the target region [1] - This transaction marks a significant breakthrough in the company's internationalization process within its biopharmaceutical strategy, contributing to both economic gains and brand value enhancement [2] Group 2: Market Expansion - The signing of the agreement aims to quickly convert the company's research and development achievements into commercial benefits through collaboration and licensing, thereby broadening the overseas market for Efparepoetin alfa [2] - The company emphasizes a dual approach of independent research and open collaboration, strengthening international partnerships to maximize product value and enhance core competitiveness [2]

证券代码：603858 证券简称：步长制药 公告编号：2025-144 山东步长制药股份有限公司 关于控股子公司注册地址及名称变更的公告 （二）名称 变更前：济南步长财淦商贸有限公司 变更后："步长青松大健康（横琴）有限公司"或"步长森林大健康（横琴） 有限公司" 以上变更信息以工商登记注册为准。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）于 2025 年 8 月 7 日召开第 五届董事会第二十八次会议，审议通过了《关于控股子公司注册地址及名称变更 的议案》，公司控股子公司济南步长财淦商贸有限公司（以下简称"步长财淦"） 因经营管理之需要，拟对其注册地址及名称进行变更，具体情况如下： 一、变更情况 （一）注册地址 变更前：山东省济南市莱芜高新区鹏泉街道汇源大街 67 号莱芜高新技术创 业服务中心 19 楼 1906-08 房间（一址多照） 变更后：广东省珠海市香洲区横琴镇 1 山东步长制药股份有限公司董事会 2025 年 8 月 8 日 2 二、授权公司董事长赵涛、总裁赵超办理 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-142 交 易 简 要 内 容 ： 公 司 控 股 子 公 司 泸 州 步 长 拟 与 菲 律 宾 公 司 GOODFELLOW 签署《独家供应协议》，泸州步长拟授权 GOODFELLOW 作为菲律宾区域内独家代理商，在目标区域内完成注射用 Efparepoetin alfa 的注册、相关临床试验、推广、分销及销售事宜。 根据协议双方的保密要求，本次交易的交易金额及交易对方主要财务数 据涉及商业秘密，按照《上市公司信息披露暂缓与豁免管理规定》《上 海证券交易所上市公司自律监管指引第 2 号——信息披露事务管理》及 《山东步长制药股份有限公司信息披露暂缓与豁免业务管理制度》相关 规定，经相应审批及登记手续，豁免披露本次交易金额及交易对方主要 财务数据。 本次交易不构成关联交易,也不构成重大资产重组。 本事项无需提交公司股东会审议批准。 山东步长制药股份有限公司 关于控股子公司泸州步长与 GOODFELLOW 签署《独家供应协议》的公告 长拟授权 GOODFELLOW 作为菲律宾区域（以下简称"目标区域"）内独家代理 商，在目标区域内完成注射用 Ef ...

山东步长制药股份有限公司 关于拟转让控股子公司股权及放弃优先受让权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603858 证券简称：步长制药 公告编号：2025-143 ●本次交易未构成关联交易，亦未构成《上市公司重大资产重组管理办法》 规定的重大资产重组。该事项无须提交股东会审议批准。 ●本次交易实施不存在重大法律障碍。 ●本次交易事项未导致公司合并报表范围发生变化，亦不会对公司财务状况 和经营成果产生重大不利影响。 一、交易概述 济南步长财淦商贸有限公司（以下简称"步长财淦"）为山东步长制药股份 有限公司（以下简称"公司"）控股子公司，公司持有其 93.00%股权，房克瑞持 有其 4.00%股权，周彦丰持有其 3.00%股权。 公司于 2025 年 5 月 19 日召开第五届董事会第二十一次会议，审议通过了《关 于公司拟转让控股子公司股权的议案》，拟将持有的控股子公司步长财淦 1%股权 转让给谢继辉。2025 年 7 月 11 日，公司与谢继辉及有关各方分别签署了《关于 济南步长财淦 ...

经与会董事研究，会议审议通过了如下议案： 证券代码：603858 证券简称：步长制药 公告编号：2025-141 山东步长制药股份有限公司 第五届董事会第二十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）第五届董事会第二十八次 会议的通知于 2025 年 8 月 1 日发出，会议于 2025 年 8 月 7 日下午 13 时以通讯 方式召开，应参会董事 9 人，实参会董事 9 人，会议由董事长赵涛先生主持。会 议出席人数、召开和表决方式符合《中华人民共和国公司法》等法律、法规及《山 东步长制药股份有限公司章程》的相关规定，合法有效。 1 、《 关 于 四 川 泸 州 步 长 生 物 制 药 有 限 公 司与 GOODFELLOW 就 注 射用 Efparepoetin alfa 签署<独家供应协议>的议案》 公 司 控 股 子 公 司 四 川 泸 州 步 长 生 物 制 药 有 限 公 司 拟 与 菲 律 宾 公司 GOODFELLOW PHARMA CORPOR ...

格隆汇8月7日丨步长制药(603858.SH)公布，公司拟以0元人民币将所持有的步长财淦2.00%股权转让给 何涛。房克瑞拟以0元人民币将步长财淦2.00%股权转让给谢继辉；周彦丰以0元人民币将步长财淦 1.00%股权转让给一九二九健康科技（广州）有限公司，公司同意放弃该股权转让的优先受让权，本次 转让完成后，公司持有步长财淦股权将由93%减少至90%。 ...

人民财讯8月7日电，步长制药（603858）8月7日晚间公告，公司控股子公司泸州步长拟与菲律宾公司 GOODFELLOW签署《独家供应协议》，泸州步长拟授权GOODFELLOW作为菲律宾区域内独家代理 商，在目标区域内完成注射用Efparepoetin alfa的注册、相关临床试验、推广、分销及销售事宜。注射用 Efparepoetin alfa适用于治疗正在接受促红细胞生成素治疗的成人透析患者因慢性肾脏病(CKD)引起的贫 血，为治疗用生物制品I类新药，目前已提交上市申请。 ...